|
WO2021043205A1
|
|
Methods for generating animal models for nonalcoholic fatty liver disease
|
|
WO2019091429A1
|
|
Unique genetic fingerprints for murine tumor model and uses thereof
|
|
US2018369423A1
|
|
Animal models for nonalcoholic fatty liver disease
|
|
WO2018177326A1
|
|
System and method for determining karenitecin sensitivity on cancer
|
|
CN110520543A
|
|
Determine gastric cancer to the system and method for Cetuximab sensibility
|
|
WO2018171555A1
|
|
Use of gut microbiota composition in immunotherapy
|
|
CN109996564A
|
|
Mice clinical test method
|
|
EP3522922A1
|
|
Novel anti-ctla4 antibodies
|
|
EP3347492A1
|
|
Methods for diagnosis of cancer
|
|
US2015282460A1
|
|
Animal model with human immune system
|
|
US2015283271A1
|
|
Method for mimicking human clinical trial by using non-human animals
|
|
WO2015149721A1
|
|
Methods for determining responsiveness to mek/erk inhibitors
|
|
KR20160003646A
|
|
Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
|
|
EP2879712A1
|
|
Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
|
